ExpressTec™ is a plant-based manufacturing technology that enables safe, affordable, and sustainable production of biologics.
Fort Collins, CO, USA, June 6, 2011 / B3C newswire / – Ventria Bioscience will showcase its ExpressTec™ biomanufacturing technology at the 4th International Plant-Based Vaccines & Antibodies (PBVA) Conference. Scott Deeter, President and CEO, will present “High Yielding and Scalable Plant-based Recombinant Protein Production in Monocots,” as part of the Facilities and Production plenary session on Friday, June 10th, 2011. The PBVA conference provides an international forum for the medical, veterinary, and plant biotechnology research communities to discuss the current state-of-the art in plant-based biologics technology and research and development related to new product development.
At the conference, Ventria Bioscience will discuss its experience scaling up a plant-based cGMP manufacturing system to commercial scale exceeding 1,000 kilograms of recombinant protein. To accomplish this scale, Ventria employs its proprietary recombinant protein manufacturing technology called ExpressTec™. ExpressTec™ provides a safe, affordable, and sustainable manufacturing platform that produces target protein yields more than ten times higher than alternative systems.
“Ventria is the first company to commercialize recombinant proteins derived from a plant-based manufacturing system and has proven this technology at large scale,” said Scott Deeter, President and CEO for Ventria Bioscience. “ExpressTec™ achieves protein yields, cost-effectiveness and safety advantages that are the foundation of a portfolio of products that were previously not available to a global customer base.”
About Ventria Bioscience
Ventria Bioscience is the first company to commercialize recombinant proteins derived from a plant-based manufacturing system. Ventria’s technology platform ExpressTec is a safe, affordable and sustainable manufacturing technology that achieves recombinant protein yield that is ten times higher than alternative systems. This advantage means Ventria’s products are accessible to a global customer base. Ventria’s product portfolio includes nine commercial products and several new products in development. Ventria’s products target three markets: human health, cell culture and biomanufacturing, and zoonotic disease.
Contact
Ventria Bioscience
320 E Vine Drive
Fort Collins, CO 80524